Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

FDA Grants Priority Review to Encorafenib/Cetuximab Combo for BRAF+ mCRC

December 19th 2019

The FDA has granted a priority review designation to a supplemental new drug application for the combination of encorafenib and cetuximab as a treatment for patients with advanced BRAF V600E–mutant metastatic colorectal cancer following up to 2 prior lines of therapy.

Dr. Kim on Immunotherapy in CRC

December 18th 2019

Richard Kim, MD, discusses the use of immunotherapy in colorectal cancer.

Dr. Benson on Treatment for Patients With Resectable Colorectal Cancer

December 18th 2019

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses treatment for patients with resectable colorectal cancer (CRC).

Dr. O'Reilly on Investigational Treatment Approaches in Pancreatic Cancer

December 18th 2019

Eileen O'Reilly, MD, associate director for clinical research and medical oncologist at Memorial Sloan Kettering Cancer Center, discusses investigational treatment approaches in advanced pancreatic cancer.

FDA Panel Backs Maintenance Olaparib for Metastatic Pancreatic Cancer

December 17th 2019

The FDA’s Oncologic Drugs Advisory Committee voted 7 to 5 in favor of olaparib tablets for an indication as a maintenance treatment of adult patients with deleterious or suspected deleterious BRCA-mutant metastatic pancreatic adenocarcinoma whose disease has not progressed on frontline platinum-based chemotherapy.

Novel Targeted Therapies Show Promise in Cholangiocarcinoma

December 17th 2019

During a recent OncLive Peer Exchange® roundtable, experts discussed novel targeted agents for cholangiocarcinomas progressing through the pipeline, such as infigratinib and pemigatinib, which are selective pan-inhibitors of FGFR fusions/translocations being evaluated in phase III trials.

Dr. Hidalgo Medina on MSI and Germline Testing in Pancreatic Cancer

December 17th 2019

Manuel Hidalgo Medina, MD, PhD, discusses microsatellite instability and germline testing patients with pancreatic cancer.

Dr. Eng on Addressing Unmet Needs for Colorectal Cancer

December 17th 2019

Cathy Eng, MD, FACP, FASCO, discusses ways to address unmet needs for young adults with colorectal cancer.

FDA Approval Sought for Ripretinib for Advanced GIST

December 16th 2019

A new drug application has been submitted to the FDA for ripretinib for use as a treatment for patients with advanced gastrointestinal stromal tumors who have previously received treatment with imatinib, sunitinib, and regorafenib.

Dr. Kim on Optimizing Outcomes With Molecular Profiling in mCRC

December 13th 2019

Richard Kim, MD, discusses how molecular profiling can be used to optimize outcomes in patients with metastatic colorectal cancer.

Dr. Unger on Utilizing a Multidisciplinary Team in Gastroesophageal Cancer

December 13th 2019

Keith R. Unger, MD, discusses utilizing a multidisciplinary team to treat patients with gastroesophageal cancer.

Dr. Corcoran on the Utility of Regorafenib in CRC

December 10th 2019

Ryan B. Corcoran, MD, PhD, discusses the utility of regorafenib in colorectal cancer.

Dr. Benson on MSI Testing in Colorectal Cancer

December 10th 2019

Al B. Benson, MD, discusses the implications of microsatellite instability testing on patients with colorectal cancer.

Dr. Ilson Discusses Challenges with Immunotherapy in Gastric Cancer

December 10th 2019

David H. Ilson, MD, PhD, discusses remaining challenges with immunotherapy in gastric cancer.

Dr. Catenacci on Treatment Selection in Esophagogastric Junction Adenocarcinoma

December 7th 2019

Daniel Catenacci, MD, discusses factors that may guide treatment selection for patients with esophagogastric junction adenocarcinoma.

Dr. Shah on Improving the Benefit of Immunotherapy in Gastric/GEJ Cancer

December 6th 2019

Manish A. Shah, MD, discusses ongoing efforts to improve immunotherapy in gastric and gastroesophageal junction cancer.

Next Steps for Wnt Research in Colorectal Cancer

December 6th 2019

Luke Dow, PhD, discusses the next steps for researching the Wnt pathway in colorectal cancer.

FDA Panel to Review Olaparib Application in Metastatic Pancreatic Cancer

December 6th 2019

The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for December 17, 2019, to discuss a supplemental new drug application for olaparib tablets as a maintenance treatment of adult patients with deleterious or suspected deleterious BRCA-mutant metastatic pancreatic adenocarcinoma whose disease has not progressed on frontline platinum-based chemotherapy.

Dr. Hidalgo Medina on Treatment Considerations in Pancreatic Cancer

December 5th 2019

Manuel Hidalgo Medina, MD, PhD, discusses treatment considerations in pancreatic cancer.

Dr. Corcoran on Promising Combination Strategies With Immunotherapy in mCRC

December 5th 2019

Ryan B. Corcoran, MD, PhD, discusses promising combination strategies with immunotherapy in metastatic colorectal cancer.